Cambium Bio Limited has released a press release.
US patent allowed for Sygenus for acne
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- RGS to receive milestone payment for successful Phase I
- Japanese Patent Office to grant key patent for Progenza
- Positive clinical trial results for Progenza
- Chinese patent granted on stem cell secretions technology
- Regeneus receives upfront payment of US$5.5m from AGC
Later from Cambium Bio
- Appendix 4E Revised
- Regeneus receives R&D tax incentive refund of $2.6m
- Sygenus shows longer lasting effect on pain than morphine
- CEO Presentation to 2017 Annual General Meeting
- Regeneus Announces Successful Results in Acne Study
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio